Ruthenium Red: Gold-Standard Calcium Transport Inhibitor for Mechanotransduction Research

Executive Summary: Ruthenium Red is a potent, dual-site inhibitor of Ca2+ transport, used extensively in studies of calcium signaling and mechanotransduction (APExBIO). It binds to two distinct sites on the Ca2+-ATPase enzyme in the sarcoplasmic reticulum, with K_m values of 4.5 μM and 2.0 mM, respectively. Its ability to block mitochondrial and erythrocyte Ca2+ uptake is concentration-dependent and highly reproducible. Ruthenium Red also exhibits anti-inflammatory effects by inhibiting capsaicin-induced plasma extravasation in vivo. The reagent's water solubility and prompt-use requirement underpin its value in advanced cellular workflows (Liu et al., 2024).

Biological Rationale

Calcium ions (Ca2+) are universal second messengers in eukaryotic cells, regulating muscle contraction, neurotransmitter release, autophagy, and cell death pathways (see related discussion). Intracellular Ca2+ homeostasis is tightly controlled by membrane transport proteins, including the Ca2+-ATPase of the sarcoplasmic reticulum (SR), mitochondrial calcium uniporters, and plasma membrane channels. Disruption of Ca2+ signaling is implicated in pathologies such as cardiac dysfunction, neurodegeneration, and chronic inflammation (Translational Insights). Ruthenium Red enables precise experimental manipulation of Ca2+ flux, supporting mechanistic studies on the interplay between cytoskeletal integrity, mechanotransduction, and autophagy (Liu et al., 2024).

Mechanism of Action of Ruthenium Red

Ruthenium Red acts as a reversible, high-affinity inhibitor of calcium ion transport across several biological membranes. It binds two distinct sites on the Ca2+-ATPase of the SR membrane—one with K_m = 4.5 μM (high-affinity) and another at K_m = 2.0 mM (low-affinity)—both located in the transmembrane, helical domain forming the Ca2+ channel (APExBIO B6740). This dual-site interaction reduces the channel's ability to sequester Ca2+, thereby inhibiting the uptake and storage of Ca2+ in vesicles and organelles. At micromolar concentrations, Ruthenium Red robustly inhibits mitochondrial Ca2+ uptake, erythrocyte Ca2+ transport, and SR vesicle Ca2+ binding. In peripheral tissues, Ruthenium Red blocks capsaicin-induced plasma extravasation, implicating its role in neurogenic inflammation (Liu et al., 2024).

Evidence & Benchmarks

• Ruthenium Red inhibits Ca2+ uptake by SR vesicles in a concentration-dependent manner, with full blockade at micromolar levels (APExBIO).
• The compound binds Ca2+-ATPase at two distinct sites: high-affinity (K_m = 4.5 μM) and low-affinity (K_m = 2.0 mM), mapped to transmembrane helices (APExBIO).
• Ruthenium Red blocks mitochondrial Ca2+ uptake, stabilizing cytosolic Ca2+ during cellular mechanotransduction (Liu et al., 2024).
• In vivo, 5 μmol/kg Ruthenium Red achieves complete inhibition of capsaicin-induced plasma extravasation in rat trachea, demonstrating anti-inflammatory effects (APExBIO).
• Ruthenium Red's inhibition of Ca2+ fluxes enables precise dissection of cytoskeleton-dependent autophagy and mechanotransduction pathways (Gold-Standard Overview), extending previous workflows with updated mechanistic clarity.

Applications, Limits & Misconceptions

Ruthenium Red is routinely used in:

• Calcium signaling research: As a selective Ca2+ channel blocker, it enables mapping of calcium-dependent pathways.
• Mitochondrial function studies: Inhibits mitochondrial Ca2+ uptake, supporting research on cellular metabolism and apoptosis.
• Autophagy and mechanotransduction: Blocks Ca2+ influx during mechanical stress to dissect cytoskeleton-dependent signaling (Liu et al., 2024).
• Inflammation models: Reduces neurogenic inflammation by preventing Ca2+-mediated plasma extravasation.

This article updates and clarifies the advanced workflows presented in "Precision Calcium Transport Inhibitor", by providing new quantitative inhibition benchmarks and addressing storage/solubility constraints.

Common Pitfalls or Misconceptions

• Ruthenium Red is not selective for a single calcium transporter; it inhibits multiple Ca2+ channels and ATPases, so off-target effects must be considered.
• It is insoluble in DMSO and ethanol; water is the only recommended solvent at ≥7.86 mg/mL (APExBIO).
• Solutions are unstable for long-term storage and should be used immediately after preparation.
• It cannot distinguish between mitochondrial and non-mitochondrial Ca2+ flux without additional experimental controls.
• Not suitable for in vivo chronic dosing due to incomplete pharmacokinetic characterization and potential toxicity at high concentrations.

Workflow Integration & Parameters

For optimal results, Ruthenium Red (B6740) should be dissolved in water at concentrations ≥7.86 mg/mL. DMSO and ethanol are unsuitable solvents. Solutions must be prepared fresh and used promptly due to limited stability. In cell-based assays, micromolar concentrations are typical for effective Ca2+ channel inhibition. For in vivo neurogenic inflammation models, a dose of 5 μmol/kg achieves complete inhibition of plasma extravasation. Always include vehicle and negative controls to discriminate non-specific effects. APExBIO provides rigorous quality controls for B6740, ensuring consistent batch-to-batch performance (APExBIO).

Conclusion & Outlook

Ruthenium Red remains the gold-standard calcium transport inhibitor for dissecting cytoskeleton-dependent mechanotransduction and autophagy. Its dual-site Ca2+-ATPase inhibition, robust anti-inflammatory action, and water solubility profile make it indispensable for advanced calcium signaling research (see comparative discussion). Future research should address selectivity and long-term in vivo applications, leveraging Ruthenium Red's strengths in acute mechanistic studies. For further details and ordering information, refer to the APExBIO Ruthenium Red (B6740) product page.